Latest news with #Genevolve
Time of India
20 hours ago
- Business
- Time of India
Dr. Lal PathLabs adds Illumina's NovaSeq X Series to expand genomics capabilities
Mumbai: Diagnostic provider Dr. Lal PathLabs Limited (DLPL) has expanded its genomics division, Genevolve , with the addition of Illumina 's NovaSeq X Series . The integration is expected to enhance the lab's capacity to deliver faster and more accurate genomic insights . The NovaSeq X system incorporates Illumina's XLEAP-SBS chemistry, offering high throughput, improved accuracy, and increased efficiency. It is stated that The NovaSeq X Plus model can process over 20,000 whole genomes per year—more than twice the capacity of Illumina's earlier models. The system is designed to support large-scale genomic research through increased speed and sensitivity. According to DLPL, the investment supports its broader efforts to improve genomic testing capabilities and contribute to the country's growing genomics landscape. Launched in 2019, DLPL's Genevolve unit focuses on DNA-based diagnostics and next-generation sequencing (NGS). The addition of Illumina's technology is expected to further strengthen its offerings in this space. Dr. Lal PathLabs and Illumina also plan to collaborate with India's scientific and medical communities to promote awareness and capacity-building for genomics-based healthcare.
Business Standard
a day ago
- Business
- Business Standard
Dr Lal Pathlabs strengthens its genomics capabilities with Illumina's NovaSeq X Series
Dr Lal Pathlabs (DLPL) has expanded its genomics capabilities by adding Illumina's NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina's latest technology, DLPL can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what's possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence, said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve's position as a pioneer in next-generation sequencing (NGS), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.
